Okyo Pharma Limited ADR (OKYO) Stock Price, Quote & News

Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acu...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 7495 2379

Website: okyopharma.com

Address:

14/15 Conduit St, Floor 4, London, United Kingdom

rp6577 Oct. 3 at 2:12 PM

$OKYO strong support at $2

0 · Reply

William_The_Great Oct. 2 at 8:55 AM

$OKYO when is the next major update? November ?

0 · Reply

William_The_Great Sep. 29 at 5:45 PM

$OKYO what’s a good time to enter ?

3 · Reply

rp6577 Sep. 27 at 3:15 PM

$OKYO with regards the recently announced bed 100 patient trial, it is labeled a "registration pathway" trial. It’s therefore designed to generate the pivotal data needed for NDA submission—effectively serving as a Phase 2/3 hybrid or standalone confirmatory study

0 · Reply

Ventureville Sep. 24 at 4:24 PM

$OKYO Always comes back to execution. $BIOV still has DPX-SurMAGE and HapTenix active, just waiting on the right partners to push faster.

0 · Reply

Vinceofmaui Sep. 24 at 1:50 PM

$PLUG OKYO Pharma Stock Rises After Company Outlines Development Pathway For Neuropathic Corneal Pain Drug $OKYO https://stocktwits.com/news/equity/markets/okyo-pharma-stock-rises-after-company-outlines-development-pathway-for-neuropathic-corneal-pain-drug/chDQvHoR32v

0 · Reply

Oscarca Sep. 23 at 10:28 AM

$OKYO

0 · Reply

StocktwitsNews Sep. 22 at 5:35 PM

OKYO Pharma Stock Rises After Company Outlines Development Pathway For Neuropathic Corneal Pain Drug $OKYO https://stocktwits.com/news/equity/markets/okyo-pharma-stock-rises-after-company-outlines-development-pathway-for-neuropathic-corneal-pain-drug/chDQvHoR32v

0 · Reply

rp6577 Sep. 22 at 5:13 PM

$OKYO starting to rally of that bottom $XBI

0 · Reply

Oscarca Sep. 22 at 2:55 PM

$OKYO https://www.globenewswire.com/news-release/2025/09/22/3153922/0/en/OKYO-Pharma-Announces-Registration-Pathway-with-100-Patient-Multi-Center-Clinical-Trial-of-Urcosimod-in-Neuropathic-Corneal-Pain.html?fbclid=IwdGRjcAM-QopleHRuA2FlbQIxMQABHlzQ5mvMCU2xcb8ukxyoCMDS_cK2OhcJJX0IWTO8-tY9HXuKOEkAFzuZ-noi_aem_gMxT8MfLq3KEiklmHpKQZw

0 · Reply

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

Jul 16, 2025, 9:21 AM EDT - 2 months ago

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

Jun 11, 2025, 10:05 AM EDT - 4 months ago

Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited

May 19, 2025, 7:00 AM EDT - 4 months ago

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

Apr 30, 2025, 7:00 AM EDT - 5 months ago

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

Mar 31, 2025, 8:00 AM EDT - 6 months ago

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

Jan 31, 2025, 7:00 AM EST - 8 months ago

OKYO Pharma Announces Chairman and CEO Acquire Shares

Jan 30, 2025, 9:45 AM EST - 8 months ago

Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited

Nov 15, 2024, 9:00 AM EST - 11 months ago

MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

MUSQ

Oct 23, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

Aug 23, 2024, 9:00 AM EDT - 1 year ago

OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

SMXT

Aug 23, 2024, 9:00 AM EDT - 1 year ago

OKYO Pharma CEO Interview to Air on Bloomberg TV

Aug 23, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces Chairman Acquires Shares

Aug 15, 2024, 12:13 PM EDT - 1 year ago

OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 6, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use

Jul 11, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101

Jul 10, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease

Apr 30, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)

Apr 8, 2024, 7:00 PM EDT - 1 year ago

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

$OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery$

Apr 2, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery

Mar 22, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Mar 21, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

Mar 20, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event

Feb 9, 2024, 7:00 AM EST - 1 year ago

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

Jan 5, 2024, 9:30 AM EST - 1 year ago

OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024

Oct 9, 2023, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)

Sep 15, 2023, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares

Sep 14, 2023, 9:15 AM EDT - 2 years ago

OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares

Sep 14, 2023, 8:45 AM EDT - 2 years ago

OKYO Pharma Limited Announces Withdrawal of Public Offering

Sep 13, 2023, 4:05 PM EDT - 2 years ago

OKYO Pharma Announces Public Offering of Ordinary Shares

Sep 8, 2023, 7:00 AM EDT - 2 years ago

OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease

Aug 30, 2023, 7:00 AM EDT - 2 years ago

OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)

Aug 15, 2023, 9:00 AM EDT - 2 years ago

OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023

Jul 28, 2023, 5:25 PM EDT - 2 years ago

OKYO Pharma Announces Proposed Public Offering of Ordinary Shares

Jul 28, 2023, 5:05 PM EDT - 2 years ago

OKYO Pharma Limited Receives Nasdaq Deficiency Notice

Jul 28, 2023, 7:01 AM EDT - 2 years ago

OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center

Jul 27, 2023, 11:30 AM EDT - 2 years ago

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer

Jun 6, 2023, 9:30 AM EDT - 2 years ago

OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease

$OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023$

May 3, 2023, 2:00 AM EDT - 2 years ago

OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023

May 2, 2023, 2:00 AM EDT - 2 years ago

OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease

Apr 25, 2023, 2:00 AM EDT - 2 years ago

OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease

Apr 18, 2023, 10:00 AM EDT - 2 years ago

OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay

Apr 5, 2023, 2:00 AM EDT - 2 years ago

Notice of General Meeting and Publication of Circular

Apr 4, 2023, 2:00 AM EDT - 2 years ago

Notice of Intention to Delist From The London Stock Exchange

Mar 30, 2023, 2:01 AM EDT - 2 years ago

OKYO Pharma Today Announces Director Acquires Shares

Mar 24, 2023, 3:00 AM EDT - 2 years ago

OKYO Pharma Announces PDMR Dealing

Mar 16, 2023, 3:01 AM EDT - 2 years ago

OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website

Mar 14, 2023, 3:00 AM EDT - 2 years ago

OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management

Mar 13, 2023, 4:15 PM EDT - 2 years ago

OKYO Pharma Limited Prices $5.3 Million Offering of ADSs

Feb 28, 2023, 2:00 AM EST - 2 years ago

OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease

rp6577 Oct. 3 at 2:12 PM

$OKYO strong support at $2

0 · Reply

William_The_Great Oct. 2 at 8:55 AM

$OKYO when is the next major update? November ?

0 · Reply

William_The_Great Sep. 29 at 5:45 PM

$OKYO what’s a good time to enter ?

3 · Reply

rp6577 Sep. 27 at 3:15 PM

0 · Reply

Ventureville Sep. 24 at 4:24 PM

$OKYO Always comes back to execution. $BIOV still has DPX-SurMAGE and HapTenix active, just waiting on the right partners to push faster.

0 · Reply

Vinceofmaui Sep. 24 at 1:50 PM

0 · Reply

Oscarca Sep. 23 at 10:28 AM

$OKYO

0 · Reply

StocktwitsNews Sep. 22 at 5:35 PM

0 · Reply

rp6577 Sep. 22 at 5:13 PM

$OKYO starting to rally of that bottom $XBI

0 · Reply

Oscarca Sep. 22 at 2:55 PM

0 · Reply

TradingRunners Sep. 22 at 2:36 PM

ECDA has only 500k shares outstanding and had news released earlier ! Spiked almost 100% in pre-market. Looks like once people find ECDA we could see a squeeze up again! Don't miss ECDA . I would rather buy before they run 300% up.. $STAI $ABP $AIRE $OKYO od

0 · Reply

Thestocktraderhubzee Sep. 22 at 12:39 PM

$OKYO OKYO Pharma Announces Plans For Next Stage Of Clinical Development For Lead Drug Candidate, Urcosimod, To Treat Neuropathic Corneal Pain

0 · Reply

rp6577 Sep. 22 at 12:33 PM

$OKYO exactly what we were waiting for! Clear route forward, which is exactly what a big Pharma partner needs

0 · Reply

rp6577 Sep. 20 at 9:35 PM

$OKYO could get very interesting from here

0 · Reply

EvieBanks6 Sep. 20 at 1:57 PM

$OKYO Setting up nicely today. Remember: discipline over emotion, process over outcome. Let’s trade smart and finish green. Stay informed about market trends and opportunities! @EvieBanks6

0 · Reply

rp6577 Sep. 19 at 9:04 PM

$OKYO Given OKYO’s Fast Track designation and the unmet need in NCP, the company is well-positioned to pursue Breakthrough Therapy Designation in Q4 2025 during or after the EOP2 meeting. An announcement could come in December 2025 alongside the earnings report, detailing FDA feedback and BTD status.

1 · Reply